Drug Trial Radar · NCT05904470
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
275
Actual
Start
May 30, 2023
Primary completion
Dec 9, 2024
Study completion Jan 28, 2025
Sponsor
- Lead sponsor
- Atea Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.
Conditions
- Chronic Hepatitis C Virus
- Hepatitis C, Chronic
- Hepatitis C
- Hepatic Cirrhosis
- HCV
Interventions
BemnifosbuvirDrug
550 mg administered orally once a day (QD) for 8 weeks
RuzasvirDrug
180 mg administered orally once a day (QD) for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)Time frame: Day 1 through 12 weeks after end of treatment
Locations
51 sites in 12 countries. Site status is shown where the registry gives one.
Atea Study Site
San Antonio, Texas
Atea Study Site
Manaus, Amazonas, Brazil
Atea Study Site
Salvador, Estado de Bahia, Brazil
Atea Study Site
Brasília, Federal District, Brazil
Atea Study Site
Rio de Janeiro, Rio Do Janeiro, Brazil
Atea Study Site
Porto Alegre, Rio Grande do Sul, Brazil
Atea Study Site
Porto Alegre, Rio Grande do Sul, Brazil
Atea Study Site
Porto Velho, Rondônia, Brazil
Atea Study Site
Boa Vista, Roraima, Brazil
Atea Study Site
Botucatu, São Paulo, Brazil
Atea Study Site
Ijuí, São Paulo, Brazil
Atea Study Site
São José do Rio Preto, São Paulo, Brazil
Atea Study Site
São Paulo, São Paulo, Brazil
Atea Study Site
São Paulo, São Paulo, Brazil
Atea Study Site
Sorocaba, São Paulo, Brazil
Atea Study Site
Vancouver, British Columbia, Canada
Atea Study Site
Toronto, Ontario, Canada
Atea Study Site
Rajkot, Gujarat, India
Atea Study Site
Surat, Gujarat, India
Atea Study Site
Belagavi, Karnataka, India
Atea Study Site
Nagpur, Maharashtra, India
Atea Study Site
Kolkata, West Bengal, India
Atea Study Site
Quatre Bornes, Mauritius
Atea Study Site
Chisinau, Moldova
Atea Study Site
Karachi, Pakistan
Atea Study Site
Karachi, Pakistan
Atea Study Site
Baguio City, Philippines
Atea Study Site
Iloilo City, Philippines
Atea Study Site
Mabalacat, Philippines
Atea Study Site
Bucharest, Romania
Atea Study Site
Bucharest, BUC, Romania
Atea Study Site
Bucharest, BUC, Romania
Atea Study Site
Constanța, CON, Romania
Atea Study Site
Craiova, DOL, Romania
Atea Study Site
Bloemfontein, Free State, South Africa
Atea Study Site
Johannesburg, Gauteng, South Africa
Atea Study Site
Randburg, Gauteng, South Africa
Atea Study Site
Somerset West, Western Cap, South Africa
Atea Study Site
Busan, South Korea
Atea Study Site
Busan, South Korea
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.